Clinical Trial Update: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating belantamab mafodotin or daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Multiple Myeloma | Phase 3 | Status: NOT_YET_RECRUITING